ReviewActa biochimica et biophysica Sinica2016
Targeting KRAS-mutant non-small cell lung cancer: challenges and opportunities.
Review in Acta biochimica et biophysica Sinica, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 20 citations in OpenAlex.
- The current landscape of using direct inhibitors to target KRASExperimental hematology & oncology · 2023Review
- Does Molecular Profiling ofCurrent oncology (Toronto, Ont.) · 2022Article
- SREBP1 regulates mitochondrial metabolism in oncogenic KRAS expressing NSCLC.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2020Article
- KRAS status is related to histological phenotype in gastric cancer: results from a large multicentre study.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2019Article
- Chromosomal instability suppresses the growth of K-Ras-induced lung adenomas.Cell cycle (Georgetown, Tex.) · 2019Article
- Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy.Molecular cancer · 2019Article
- Review
- KRAS induces lung tumorigenesis through microRNAs modulation.Cell death & disease · 2018Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Oncogenic mutations in Kirsten rat sarcoma viral oncogene homolog (KRAS) occur in 15%-30% of non-small cell lung cancer (NSCLC). However, despite decades of intensive research, there is still no direct KRAS inhibitor with clinically proven efficacy. Considering its association with poor treatment response and prognosis of lung cancer, developing an effective inhibitory approach is urgently needed. Here, we review different strategies currently being explored to target KRAS-mutant NSCLC, discuss opportunities and challenges, and also propose some novel methods and concepts with the promise of clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.